The Company

StemBioSys, LLC has developed innovative, proprietary stem cell technologies for research and therapeutic pipelines.

Developed in U.S. university medical centers, our technology can significantly advance ongoing research and bring us closer to realizing the stem cell therapy promise. Learn More

News & Events

  • Xiao-Dong Chen, MD, PhD,  leads Shanghai Symposium 

  • StemBioSys, LLC signs licensing agreement 

  • T3DC grants first investment to StemBioSys 

    Learn more

    • Our Technology

    StemBioSys, LLC 's unique technologies can isolate large numbers of highly pluripotent mesenchymal stem cells (MSCs) from human umbilical cord blood (hUCB) and expand their number with an optimized culture medium.

    Using a patent pending 3‐dimensional extracellular matrix (ECM) generated by bone marrow‐derived fibroblasts, StemBioSys technologies can isolate 200,000‐fold more MSCs from hUCB than can be isolated using plastic adhesion... Learn More

    Our Products

    • A superior ECM.
      Our true 3-dimension extra-cellular (XC-marrow-ECM™) has been documented to expand stem cell lines significantly faster than conventional growth media and maintains excellent retention of "stemness". Learn more
    • Native, pluripotent MSCs 
      StemBioSys human MSCs are native, not induced (iPS)   They are embryonic-like mesenchymal stem cells derived from human
      umbilical cord blood      .   Learn more